日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions.

AZ14289671 是一种高选择性且能穿透血脑屏障的不可逆 TKI,靶向 EGFRExon20 插入

Swaih Aisha M, Talbot Sara, Savoca Adriana, Thorpe Hannah, Flemington Vikki, Phillips Benjamin, Colclough Nicola, McCoull William, Radeva Veronika, Hargreaves David, Packer Martin J, Felisberto-Rodrigues Catarina, Thomson Clare, Orme Jonathan P, Deane Carly, Smith Aaron, Johnström Peter, Schou Magnus, McWilliams Lisa, Davey Paul, Enget Marianne, O'Neill Daniel, Cosulich Sabina, Floc'h Nicolas

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes

新发 1 型糖尿病中 CD8 T 细胞部分耗竭和对替普利珠单抗的临床反应

S Alice Long, Jerill Thorpe, Hannah A DeBerg, Vivian Gersuk, James Eddy, Kristina M Harris, Mario Ehlers, Kevan C Herold, Gerald T Nepom, Peter S Linsley